Literature DB >> 33597569

Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study.

Tian-Hua Yu1, Xin Chen2, Xuan-He Zhang3, Er-Chi Zhang4, Cai-Xia Sun5.   

Abstract

We aimed to explore the clinicopathological features and survival-related factors for intrahepatic cholangiocarcinoma (ICC). Eligible data were extracted from the Surveillance, Epidemiology and End Results (SEER) database from 2004 to 2015. Totally, 4595 ICC patients were collected with a male to female ratio of nearly 1:1. The higher proportion of ICC patients was elderly, tumor size ≥ 5 cm and advanced AJCC stage. Most patients (79.2%) have no surgery, while low proportion of patients receiving radiotherapy (15.1%). The median survival was 7.0 months (range 0-153 months). The 5-year CSS and OS rates were 8.96% and 7.90%. Multivariate analysis found that elderly age (aged ≥ 65 years old), male, diagnosis at 2008-2011, higher grade, tumor size ≥ 5 cm, and advanced AJCC stage were independent factors for poorer prognosis; while API/AI (American Indian/AK Native, Asian/Pacific Islander) race, married, chemotherapy, surgery and radiotherapy were independent favorable factors in both CSS and OS. Furthermore, stratified analysis found that chemotherapy and radiotherapy improved CSS and OS in patients without surgery. Age, sex, race, years of diagnosis, married status, grade, tumor size, AJCC stage, surgery, chemotherapy and radiotherapy were significantly related to prognosis of ICC. Chemotherapy and radiotherapy could significantly improve survival in patients without surgery.

Entities:  

Mesh:

Year:  2021        PMID: 33597569      PMCID: PMC7889915          DOI: 10.1038/s41598-021-83149-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  36 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

2.  Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience.

Authors:  Hüseyin Bektas; Cemil Yeyrek; Moritz Kleine; Florian W R Vondran; Kai Timrott; Nora Schweitzer; Arndt Vogel; Mark D Jäger; Harald Schrem; Jürgen Klempnauer; Lampros Kousoulas
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-08-27       Impact factor: 7.027

3.  Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Authors:  S Song; K Kim; E K Chie; S Kim; H J Park; N J Yi; K-S Suh; S W Ha
Journal:  Clin Transl Oncol       Date:  2015-06-04       Impact factor: 3.405

4.  Growing Evidence Supports the Use of Radiation Therapy in Unresectable Intrahepatic Cholangiocarcinoma.

Authors:  Kyle C Cuneo; Theodore S Lawrence
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

5.  Pediatric low-grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database.

Authors:  Roy W R Dudley; Michelle R Torok; Danielle R Gallegos; Jean M Mulcahy-Levy; Lindsey M Hoffman; Arthur K Liu; Michael H Handler; Todd C Hankinson
Journal:  Neurosurgery       Date:  2015-03       Impact factor: 4.654

6.  Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma.

Authors:  Matthew W Jackson; Arya Amini; Bernard L Jones; Chad G Rusthoven; Tracey E Schefter; Karyn A Goodman
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

Review 7.  The epidemiology of cholangiocarcinoma.

Authors:  Yasser Shaib; Hashem B El-Serag
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

8.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

Authors:  Yasser H Shaib; Jessica A Davila; Kathryn McGlynn; Hashem B El-Serag
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

9.  Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching.

Authors:  Feng Shao; Wei Qi; Fu Tao Meng; Lujun Qiu; Qiang Huang
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

10.  Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: A SEER database analysis.

Authors:  Rui Cheng; Qiang Du; Jingmin Ye; Bi Wang; Yanling Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

View more
  4 in total

1.  Diffusion-weighted imaging as an imaging biomarker for assessing survival of patients with intrahepatic mass-forming cholangiocarcinoma.

Authors:  Julaluck Promsorn; Kulyada Eurboonyanun; Payia Chadbunchachai; Chaiwat Apivatanasiri; Kosin Wirasorn; Jarin Chindaprasirt; Aumkhae Sookprasert; Mukesh Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2022-06-15

Review 2.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

3.  MicroRNA-7-5p Inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by Inhibiting MyD88.

Authors:  Yi Tang; Zhenyong Tang; Jianrong Yang; Tianqi Liu; Yuntian Tang
Journal:  J Clin Transl Hepatol       Date:  2021-05-10

4.  Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy.

Authors:  Maximilian N Kinzler; Christina Klasen; Falko Schulze; Eva Herrmann; Andreas A Schnitzbauer; Jörg Trojan; Stefan Zeuzem; Peter J Wild; Dirk Walter
Journal:  J Clin Med       Date:  2022-04-06       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.